Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality - A 21-year follow-up of 8000 men

被引:313
作者
Goldbourt, U
Yaari, S
Medalie, JH
机构
[1] TEL AVIV UNIV, SACKLER FAC MED, HENRY N NEUFELD CARDIAC RES INST, IL-52621 TEL HASHOMER, ISRAEL
[2] TEL AVIV UNIV, SACKLER FAC MED, DEPT EPIDEMIOL & PREVENT MED, IL-52621 TEL HASHOMER, ISRAEL
[3] BAR ILAN UNIV, CTR COMP, RAMAT GAN, ISRAEL
[4] CASE WESTERN RESERVE UNIV, DEPT FAMILY MED, CLEVELAND, OH 44106 USA
关键词
HDL cholesterol; coronary heart disease; long-term mortality; preventive strategies;
D O I
10.1161/01.ATV.17.1.107
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
For the purpose of screening individuals at high risk for coronary heart disease (CHD), serum total cholesterol (TC) of 5.2 mmol/L has been set as a value dividing ''desirable'' from intermediate high or elevated levels, and HDL cholesterol (HDL-C) <0.9 mmol/L has been labeled as abnormally low, implying high CHD risk. It has been conjectured that low HDL-C poses no risk in the absence of elevated LDL cholesterol or TC. To assess the risk of CHD-free men with ''isolated low HDL-C,'' ie, abnormally low HDL-C with desirable TC, we examined the CHD and all-cause mortality of some 8000 Israeli men aged 42 years and older during 1965 through 1986. Men with isolated low HDL-C represented one sixth of the cohort. CHD mortality among these men was 36% higher (age adjusted) than in counterparts with desirable TC, of which >0.9 mmol/L was contained in the high-density fraction. In men with TC>5.2 mmol/L, abnormally low HDL-C was associated with a virtually identical CHD mortality risk ratio, 38%. These findings persisted after adjustment for multiple CHD risk factors. The excess CHD risk associated with isolated low HDL-C appeared particularly increased in men with diabetes mellitus, whose death rate was 65% higher than in diabetics with HDL-C >0.9 mmol/L. A second subgroup result was consistent with equal CHD mortality risk among men in the ''desirable'' TC range, with or without low HDL-C, if systolic blood pressure was >160 mm Hg. These are post hoc findings, and hypotheses arising from these observations would require independent examination. Total mortality was not increased in men with isolated low HDL-C compared with men who had HDL-C <0.9 mmol/L and TC >5.2 mmol/L at baseline. These results indicate that an increased risk of CHD death is associated with abnormally low HDL-C for cholesterol ranges both below and above 5.2 mmol/L. For the individual, therefore, the risk is multiplied by the same amount regardless of TC. Quitting smoking, increasing physical activity, and decreasing body weight would all contribute to raise HDL-C in individuals of most or all age groups. When examined from a community perspective, the results are consistent with a relatively low population-attributable fraction among CHD-free men. This would tend to support the recommended practice of considering a TC level of 5.2 mmol/L (200 mg/dL) as a threshold for further evaluation in screened individuals without manifest CHD.
引用
收藏
页码:107 / 113
页数:7
相关论文
共 32 条
  • [1] AGMON J, 1992, CIRCULATION, V86, P839
  • [2] ANDERSON JT, 1962, CLIN CHEM, V21, P145
  • [3] BIOLOGICAL AND CULTURAL SOURCES OF FAMILIAL RESEMBLANCE IN PLASMA-LIPIDS - A COMPARISON BETWEEN NORTH-AMERICA AND ISRAEL - THE LIPID-RESEARCH-CLINICS-PROGRAM
    BUCHER, KD
    FRIEDLANDER, Y
    KAPLAN, EB
    NAMBOODIRI, KK
    KARK, JD
    EISENBERG, S
    STEIN, Y
    RIFKIND, BM
    [J]. GENETIC EPIDEMIOLOGY, 1988, 5 (01) : 17 - 33
  • [4] SUR UN DOSAGE RAPIDE DU CHOLESTEROL LIE AUX ALPHA-LIPOPROTEINES ET AUX BETA-LIPOPROTEINES DU SERUM
    BURSTEIN, M
    SAMAILLE, J
    [J]. CLINICA CHIMICA ACTA, 1960, 5 (04) : 609 - 609
  • [5] COX DR, 1972, J R STAT SOC B, V34, P187
  • [6] HYPERTRIGLYCERIDEMIA AS A RISK FACTOR OF CORONARY HEART-DISEASE MORTALITY IN SUBJECTS WITH IMPAIRED GLUCOSE-TOLERANCE OR DIABETES - RESULTS FROM THE 11-YEAR FOLLOW-UP OF THE PARIS PROSPECTIVE-STUDY
    FONTBONNE, A
    ESCHWEGE, E
    CAMBIEN, F
    RICHARD, JL
    DUCIMETIERE, P
    THIBULT, N
    WARNET, JM
    CLAUDE, JR
    ROSSELIN, GE
    [J]. DIABETOLOGIA, 1989, 32 (05) : 300 - 304
  • [7] HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE
    FRICK, MH
    ELO, O
    HAAPA, K
    HEINONEN, OP
    HEINSALMI, P
    HELO, P
    HUTTUNEN, JK
    KAITANIEMI, P
    KOSKINEN, P
    MANNINEN, V
    MAENPAA, H
    MALKONEN, M
    MANTTARI, M
    NOROLA, S
    PASTERNACK, A
    PIKKARAINEN, J
    ROMO, M
    SJOBLOM, T
    NIKKILA, EA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) : 1237 - 1245
  • [8] GAHLINGER PM, 1993, COMPUTER PROGRAMS EP, P119
  • [9] CHOLESTEROL AND CORONARY HEART-DISEASE MORTALITY - A 23-YEAR FOLLOW-UP-STUDY OF 9902 MEN IN ISRAEL
    GOLDBOURT, U
    YAARI, S
    [J]. ARTERIOSCLEROSIS, 1990, 10 (04): : 512 - 519
  • [10] RATIONALE AND DESIGN OF A SECONDARY PREVENTION TRIAL OF INCREASING SERUM HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL AND REDUCING TRIGLYCERIDES IN PATIENTS WITH CLINICALLY MANIFEST ATHEROSCLEROTIC HEART-DISEASE (THE BEZAFIBRATE INFARCTION PREVENTION TRIAL)
    GOLDBOURT, U
    BEHAR, S
    REICHERREISS, H
    AGMON, J
    KAPLINSKY, E
    GRAFF, E
    KISHON, Y
    CASPI, A
    WEISBORT, J
    MANDELZWEIG, L
    ABINADER, E
    AHARON, L
    BRAUN, S
    DAVID, D
    FLICH, M
    FRIEDMAN, Y
    KRISTAL, N
    LEIL, N
    MARKIEWICZ, W
    MARMOR, A
    PALANT, A
    PELLED, B
    RABINOWITZ, B
    REISIN, L
    ROGUIN, N
    ROSENFELD, T
    SCHLESINGER, Z
    SCLAROVSKY, S
    SHERF, L
    TZIVONI, D
    ZAHAVI, I
    ZION, M
    BRUNNER, D
    FRIDENSOHN, A
    JAFARI, J
    OSTFELD, B
    ROCHFLEISH, S
    SCHNEIDER, H
    KHALID, S
    NARINSKY, R
    ROTZAK, R
    VITRAI, J
    PELLED, B
    PARDU, J
    LANIADO, S
    ESHCHAR, Y
    ARDITI, A
    BOTWIN, S
    ROGUIN, N
    YAHALOM, M
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1993, 71 (11) : 909 - 915